-
BOC/BOA 2024 | Dr. Zhitao Ying: Annual Advances in Chinese Clinical Oncology 2023——B-Cell Lymphoma, T and NK Cell Lymphomas
Since 2015, the Chinese Society of Clinical Oncology (CSCO) has been dedicated to presenting annual reports on the progress of clinical oncology in China, under the theme “International Standards, Chinese Characteristics, Learning and Innovation.” At the recent “2024 Annual Progress in Chinese Clinical Oncology Conference (BOC) and Best of ASCO 2024 China,” the latest “Annual…
-
Today, we join the global community in recognizing World Hepatitis Day
Today, we join the global community in recognizing World Hepatitis Day. This year’s theme, “Eliminate Hepatitis · Take Action Positively,” underscores the importance of proactive measures in combating this liver…
-
Dr. Xuefeng Luo: Advances in Gastric Variceal Bleeding Treatment – Cyanoacrylate Injection vs. Interventional Therapy
To keep medical professionals updated on the latest advancements in interventional therapy for liver diseases, Hepatology Digesthas launched the Interventional Therapy for Liver and Gallbladder Diseases column in collaboration with…
-
Professor Michael Heneghan: Advancing Autoimmune Hepatitis Research
Autoimmune hepatitis (AIH) presents ongoing challenges in diagnosis and treatment, requiring continuous research to improve patient outcomes. Professor Michael A. Heneghan has been a leading voice in AIH research, providing…
-
2024 CACA Integrated Breast Cancer Conference | Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management
The Chinese Anti-Cancer Association, adhering to the tenet of “prevention, screening, diagnosis, treatment, and rehabilitation,” has launched the “Chinese Tumor Integrated Diagnosis and Treatment Guidelines.” At the 2024 CACA Integrated Breast Cancer Conference, “Oncology Frontier” invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University,…
-
Professor Sifeng Tao and Hui Liu Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast Cancer
Oncology Frontier: Regarding intensified adjuvant treatment (including initial high-risk and non-pCR after neoadjuvant therapy), the A-BRAVE study on immunotherapy was reported at this year’s ASCO conference. What do you think…
-
BOC/BOA 2024 | Professor Chen Xun: Dual Immunotherapy Brings New First-Line Option for Advanced Liver Cancer
01 Oncology Frontier: Could you briefly summarize the main findings of the CheckMate 9DW study? What advantages does this combination therapy have over lenvatinib or sorafenib? Professor Chen Xun: The…
-
EASL Liver Cancer Summit | Professor Abdel Ghani Atef: FibroScan Aids in Early Screening of Liver Cancer
Hepatocellular carcinoma (HCC), the most common primary malignant liver tumor, is one of the leading causes of death in patients with cirrhosis. Non-invasive diagnostic tools such as transient elastography (FibroScan) have shown great promise in identifying patients at high risk of HCC. Recently, the 2025 EASL Liver Cancer Summit was held in Paris, France. Professor…
Connecting Medical Expertise through Media